四川宝兴虎耳草对大鼠慢性增生性前列腺炎的药理作用研究
|
摘要
目的：通过建立大鼠慢性增生性前列腺炎模型,探讨宝兴虎耳草对慢性增生性前列腺炎的药理作用。
方法：(1)慢性增生性前列腺炎模型建立选取雄性SD大鼠作为模型动物,将大鼠全麻保定确实后,无菌操作打开腹腔,于前列腺左、右两叶分别注入0.2ml消痔灵注射液,假手术对照组则注射等体积生理盐水,0.05%碘伏按压针眼,缝合腹壁肌肉和皮肤,12h后可自由饮食,术后每天用碘酊消毒创口,防止感染。通过与正常组进行比较,判定模型是否建立成功,筛选出最佳慢性增生性炎症病理模型建立方法。(2)药液制备将虎耳草水煎液熬制成100%的水煎液(即1mL煎液相当于生药1g)。(3)药效观察将体况相近的45只模型大鼠作为治疗组,分为9不同的组,即持续7天给药的高、中、低三组,和持续14、21天给药的高、中、低剂量组,每组5只。同时,将15只假手术组大鼠分成3组,每组5只分别作为持续7天、14天、21天给药的假手术对照组,另外15只模型大鼠则不给药,作为持续7天、14天、21天给药的模型对照组。(4)灌胃给药低剂量组1ml/只,中剂量组2ml/只,高剂量组4ml/只,灌胃给药,早晚各一次。(5)治疗效果的判定根据前列腺组织病理学变化、前列腺液白细胞总数和卵磷脂小体密度、前列腺指数、血清前列腺酸性磷酸酶(ACP)和超氧化物歧化酶(SOD)活力,丙二醛(MDA)和睾酮(T)含量,判定治疗效果,比较不同剂量和持续给药时间的治疗效果,筛选出最佳给药浓度和持续给药时间。
结果：通过向前列腺两叶注射0.2ml消痔灵注射液成功建立大鼠慢性增生性前列腺炎模型；虎耳草水煎液各剂量和不同长短持续给药时间均表现出一定的治疗效果,低剂量组持续给药7天效果不明显,血清中的SOD活力和ACP水平与模型组差别不大,前列腺组织炎性病变较为严重,但白细胞总数和前列腺指数都有不程度的减小,而卵磷脂小体密度略有增加,血清睾酮水平也有所上升；给药14天以后,则可明显提高血清中SOD活力和睾酮含量,降低血清ACP和MDA,同时使前列腺组织炎性病变减轻,卵磷脂小体密度回升。随着治疗剂量的增加和持续给药时间的延长,治疗效果更为显著。以高剂组治疗效果最为明显,特别是持续给药21天,各项指标均趋近于正常,与模型组比较呈极显著性差异(P<0.01)。
结论：虎耳草水煎液对大鼠慢性增生性前列腺炎有一定的治疗作用,随着给药剂量的加大和持续给药时间的延长,治疗效果愈趋显著。特别是高剂量(4g/只)持续灌胃21天以后,各项指标均趋近于正常。
Objective:A Pathological Model of Rats with chronic and proliferative prostatitis was established to study the effect to Saxifraga stolonifera on the model.
Method:(1) Model of chronic and proliferative prostatitis:Selected male SD rats as model animal, after been anesthetized and restraint, open peritoneal cavity by sterile working. Then inject hemorrhoid injection 0.2ml to left and right lobe of prostate, while injecting equal-volume physiological saline into sham operated control group rats, and suture abdominal wall muscles and skin. Ingestation freely after 12h for operation, and sterilized wound to prevent infection. The model were determined succeed or not by compared with the normal groups, and screening the best method. (2) Physic liquor preparation:Decocting saxifrage to 100% water solution, it means there is 1g saxifrage in 1ml water solution. (3) Potency observation:Select 45 rats with similar body condition as the treatment group and divide them into 9 different groups, namely 7 days group,14 days group and 21 days group,and divide every group into high-dose group、middle-dose group and low-dose group,5 rats in every group. Meanwhile, the 15 sham operated rats for comparison were divided into 3 groups, such as 7 days group,14 days group and 21 days group,5 rats in every group. In addition, select 15 operation rats without medication as model group, and the grouping method just as the control group. (4) Intragastric administration with saxifraga stolonifera water solution in every night and morning. 1ml for a rat of low-dose group,2ml for a rat of middle-dose group and 4ml for a rat of high-dose group. (5) Determination of the treatment effect:The treatment effect could be determinated by those index as follows: pathological changes of prostate tissue, total white blood cells count and lecithin density of prostatic fluid, the activity of Serum prostatic acid phosphatase (ACP) and superoxide dismutase (SOD), and malondialdehyde (MDA) and testosterone (T) levels. Meanwhile, according to those index mentioned above, the treatment effect of different doses and sustained administration time could be compared.
Results:The model of chronic prostatitis hyperplasia was successfully established by injecting hemorrhoid injection in two lobe of Prostate. Saxifrage decoction of different each dose group and sustained medication time indicated certain efficacy. Low-dose group for 7 days continue medication indicated little effect, and it could be seen that SOD and testosterone levels in blood serum were increased, ACP and MDA in blood serum were decreased, and lecithin density was rebound and inflammatory lesion of prostate was mitigated after continue medication for 14 days. As the dose increased and longer continue medication time, the treatment effect was more significant than before. The effect of high dose treatment group was most significant, especially the time of continue medication was 21 days, for all treatment indexs closing to normal,which showed great significant difference compared with the model group (P<0.01). Conclusion:Saxifrage decoction of different each dose group and sustained medication time indicated certain efficacy, as to the increased dose and extend continue medication, more significant has been discovered. Especially the time of continue medication was 21 days, for all treatment index closing to normal, which showed great significant difference compared with the model group.
方法：(1)慢性增生性前列腺炎模型建立选取雄性SD大鼠作为模型动物,将大鼠全麻保定确实后,无菌操作打开腹腔,于前列腺左、右两叶分别注入0.2ml消痔灵注射液,假手术对照组则注射等体积生理盐水,0.05%碘伏按压针眼,缝合腹壁肌肉和皮肤,12h后可自由饮食,术后每天用碘酊消毒创口,防止感染。通过与正常组进行比较,判定模型是否建立成功,筛选出最佳慢性增生性炎症病理模型建立方法。(2)药液制备将虎耳草水煎液熬制成100%的水煎液(即1mL煎液相当于生药1g)。(3)药效观察将体况相近的45只模型大鼠作为治疗组,分为9不同的组,即持续7天给药的高、中、低三组,和持续14、21天给药的高、中、低剂量组,每组5只。同时,将15只假手术组大鼠分成3组,每组5只分别作为持续7天、14天、21天给药的假手术对照组,另外15只模型大鼠则不给药,作为持续7天、14天、21天给药的模型对照组。(4)灌胃给药低剂量组1ml/只,中剂量组2ml/只,高剂量组4ml/只,灌胃给药,早晚各一次。(5)治疗效果的判定根据前列腺组织病理学变化、前列腺液白细胞总数和卵磷脂小体密度、前列腺指数、血清前列腺酸性磷酸酶(ACP)和超氧化物歧化酶(SOD)活力,丙二醛(MDA)和睾酮(T)含量,判定治疗效果,比较不同剂量和持续给药时间的治疗效果,筛选出最佳给药浓度和持续给药时间。
结果：通过向前列腺两叶注射0.2ml消痔灵注射液成功建立大鼠慢性增生性前列腺炎模型；虎耳草水煎液各剂量和不同长短持续给药时间均表现出一定的治疗效果,低剂量组持续给药7天效果不明显,血清中的SOD活力和ACP水平与模型组差别不大,前列腺组织炎性病变较为严重,但白细胞总数和前列腺指数都有不程度的减小,而卵磷脂小体密度略有增加,血清睾酮水平也有所上升；给药14天以后,则可明显提高血清中SOD活力和睾酮含量,降低血清ACP和MDA,同时使前列腺组织炎性病变减轻,卵磷脂小体密度回升。随着治疗剂量的增加和持续给药时间的延长,治疗效果更为显著。以高剂组治疗效果最为明显,特别是持续给药21天,各项指标均趋近于正常,与模型组比较呈极显著性差异(P<0.01)。
结论：虎耳草水煎液对大鼠慢性增生性前列腺炎有一定的治疗作用,随着给药剂量的加大和持续给药时间的延长,治疗效果愈趋显著。特别是高剂量(4g/只)持续灌胃21天以后,各项指标均趋近于正常。
Objective:A Pathological Model of Rats with chronic and proliferative prostatitis was established to study the effect to Saxifraga stolonifera on the model.
Method:(1) Model of chronic and proliferative prostatitis:Selected male SD rats as model animal, after been anesthetized and restraint, open peritoneal cavity by sterile working. Then inject hemorrhoid injection 0.2ml to left and right lobe of prostate, while injecting equal-volume physiological saline into sham operated control group rats, and suture abdominal wall muscles and skin. Ingestation freely after 12h for operation, and sterilized wound to prevent infection. The model were determined succeed or not by compared with the normal groups, and screening the best method. (2) Physic liquor preparation:Decocting saxifrage to 100% water solution, it means there is 1g saxifrage in 1ml water solution. (3) Potency observation:Select 45 rats with similar body condition as the treatment group and divide them into 9 different groups, namely 7 days group,14 days group and 21 days group,and divide every group into high-dose group、middle-dose group and low-dose group,5 rats in every group. Meanwhile, the 15 sham operated rats for comparison were divided into 3 groups, such as 7 days group,14 days group and 21 days group,5 rats in every group. In addition, select 15 operation rats without medication as model group, and the grouping method just as the control group. (4) Intragastric administration with saxifraga stolonifera water solution in every night and morning. 1ml for a rat of low-dose group,2ml for a rat of middle-dose group and 4ml for a rat of high-dose group. (5) Determination of the treatment effect:The treatment effect could be determinated by those index as follows: pathological changes of prostate tissue, total white blood cells count and lecithin density of prostatic fluid, the activity of Serum prostatic acid phosphatase (ACP) and superoxide dismutase (SOD), and malondialdehyde (MDA) and testosterone (T) levels. Meanwhile, according to those index mentioned above, the treatment effect of different doses and sustained administration time could be compared.
Results:The model of chronic prostatitis hyperplasia was successfully established by injecting hemorrhoid injection in two lobe of Prostate. Saxifrage decoction of different each dose group and sustained medication time indicated certain efficacy. Low-dose group for 7 days continue medication indicated little effect, and it could be seen that SOD and testosterone levels in blood serum were increased, ACP and MDA in blood serum were decreased, and lecithin density was rebound and inflammatory lesion of prostate was mitigated after continue medication for 14 days. As the dose increased and longer continue medication time, the treatment effect was more significant than before. The effect of high dose treatment group was most significant, especially the time of continue medication was 21 days, for all treatment indexs closing to normal,which showed great significant difference compared with the model group (P<0.01). Conclusion:Saxifrage decoction of different each dose group and sustained medication time indicated certain efficacy, as to the increased dose and extend continue medication, more significant has been discovered. Especially the time of continue medication was 21 days, for all treatment index closing to normal, which showed great significant difference compared with the model group.
引文
[1]丁家欣,张立石,张玲,等.虎耳草提取物对前列腺癌细胞凋亡的影响[J].中国中医基础医学杂志,2005,11(12)：905-905,907。
[2]居龙涛.虎耳草制剂治疗前列腺增生症[J].中国中医基础医学杂志,2007,13(1)：79-79.
[3]张立石,丁家欣,张秋海,等.虎耳草提取物对大鼠成纤维细胞的抑制作用[J].中国中医基础医学杂志,2005,11(12)：920-922.
[4]Morita N, et al. Chem Pharm Bull.1974,22(7):1487.
[5]罗厚蔚,吴葆金,陈节庵等.虎耳草有效成分研究[J].中国药科大学学报,1988,199(1)：1.
[6]周光兴.比较组织学彩色图谱[M].复旦大学出版社,2002：126.
[7]眭元庚.前列腺的组织结构、功能与疾病的关系[J].实用老年医学,2005,19(4)：172-173.
[8]厉将斌.慢性前列腺炎的中医认识和治疗思路[J].云南中医学院学报,2003,26(2)：29-31.
[9]陈武山.现代名中医男科学[M].北京：科学技术文献出版社,2002,1：124-125.
[10]王琦.临床医学丛书[M].北京：人民卫生出版社,2003,1：1213-1218.
[11]蒋毅,王久源,张蜀武,等.非淋煎口服液治疗衣原体、支原体感染性前列腺炎的临床应用研究[J].中华男科学,2003,9(4)：309-315.
[12]谭燕泉.清热解毒杀虫为法拟方内服外洗治疗滴虫性前列腺炎38例[J].安徽中医临志,2002,14(6)：465.
[13]邓春华,辛钟成,李宏军.男科病诊治学[M].广州：羊城晚报出版社,2004,1：393-401.
[14]郭应禄,李宏军,箭列腺炎[M].北京：人民军医出版社,2002,1：89-98.
[15]Collins MM. How common is prostatitis, A national survey of physician Visits[J]. J Urol. 1998,159(4):1224.
[16]Drach GW, Fair WR, Meares EM Jr, et al. Classification of benign disease associated with prostatic pain,prostatitis or prostatodynia[J]. J Urol.1978,120:266-270.
[17]Neisser A.Die Mikrokokken der ginorrhoe[J]. Dtsch Med Wochenser,1882,8:279-282.
[18]Meares EM,Stamey TA.Bacteriologic localization patterns in bacterial prostatitis and urethritis[J]. Invest Urol,1968,5(5):492-518.
[19]Blacklock NJ. The anatomy of the prostate:relation-ship with prostatic infection[J]. infection,1991,19:111-114.
[20]Zabokowski T,Peterek J,Srawarz B. The results of treatment of chronic prostatitis on the background of anaerobic bacterial and fugal infections[J]. WiadLek,1999,52:456-461.
[21]Nickel JC. Prostatitis:lessons from the 20th century[J]. Br Jurol,2000,85:179-185.
[22]Ye ZQ,Cai D,Lan RZ.et al. Biofeedbacktherapy for bacterial and nonbacterial prostatitis[J]. Urol,2000,85:179-185.
[23]Jackson E,Fowler JR.Antimicrobial therapy for bacterial and nonbacterial prostatitis[J]. Urol,2002,60(Suppl 6A):24-26.
[24]Nickel JC, Pontari M, Moon T, et al. A randomized placebo controlled multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic non-bacterial prostatitis[J]. Urol,2003,169(4):1401-1405.
[25]Shoskes DA. Phytotherapy in chronic prostatitis[J]. Uro,2002,60(6 Suppl):35-37.
[26]Nadler RB. Bladder training biofeedback and pelvic floor myalgia[J]. Urol,200260(6 Suppl):42-43.
[27]Zeitlin SI.Heat therapy in the treatment of prostatitis[J].Urol,2002,60 (6Suppl):38-40.
[28]Ye ZQ,Cai D,Lan RZ,et al. Biofeedback therapy for chronic pelvic pain Syndrome[J].Asian J Androl,2003,5(2):155-158.
[29]Mcnaughton Collins M,Wilt T.Allopurinol for chronic prostatitis[J].Cochrane Database Syst Rev,2000,2:1039-1041.
[30]Sboskes DA,Zeitlin SI,Shahed A,et al. Quercetin in men withcategoryⅢchronic prostatitis,a prelimi nary prospective,double-blind,place-controled trial[J].Urol,1999,54:960-963.
[31]于寿昌.慢性细菌性前列腺炎的感染菌调查[J].男性学杂志,1997,11：112.
[32]Zhang YY, Wang F, Zhang JD, et al.In vitro antibacterial activity of Levofloxacin[J]. Drugs, 1995,49 Suppl 2:274-275.
[33]那彦群,韩铁山,周利群,等.泰利必妥治疗慢性前列腺炎[J].中华泌尿外科杂志,1993,14(2)：144.
[34]吕建林.中西医结合治疗慢性细菌性前列腺炎[J].辽宁中医志,2003,9：755-756.
[35]吴在德.外科学(第5版)[M].北京：人民卫生出版社,2001.
[36]喻明清.中药灌肠结合头孢噻肟钠治疗慢性前列腺炎35例[J].广西中医学院学报,2003,6(2)：21-22.
[37]王庆相.慢性前列腺炎中西医结合治疗探讨[J].中国中西医结合外科杂志,2003,9(3)：200-201.
[38]潘锦堂.中国虎耳草属的研究[J].植物分类学报,1991,29(1)：1-24.
[39]刘文江,段育宏.中药百两金的药理作用[J].中草药,1986,17(9)：21.
[40]Lim H K. Ethnopharmacol,2000,72(3):469-474.
[41]湖南卫生局.矮地茶治疗老年性气管炎临床和试验研究资料[M].1972：46.
[42]吴春,孔琪,李健,等.槲皮素微胶囊的稳定性及缓释性能研究[J].化学与黏合,2006,28(1)：11-13.
[43]朱蕾,何丽娅.槲皮素抗癌作用的分子机制[J].武汉科技大学学报(自然科学),2004,27(2)：194-197.
[44]刘世旺,徐艳霞.虎耳草乙醇提取物抑菌作用的研究[J].资源开发与市场,2007,23(6)：481-482,489.
[45]刘世旺,徐艳霞,石宏武.虎耳草乙醇提取物对细菌生长曲线的影响[J].安徽农业科学,2007,35(4)：943-944,946.
[46]宋传旺.槲皮素对LPS延迟中性粒细胞自发性凋亡效应的抑制作用[J].中国免疫学杂志,2005,21：14-16.
[47]谢明辉.国外医药[J].植物药分册2002,17(6)：275.
[48]李宏军,商学军,黄宁烽.IL-10、IL-8在慢性前列腺炎中的改变及意义[J].中华男科学,2004，10：486-490.
[49]杨进益,叶林,姜洪波,等.慢性前列腺炎患者前列腺液Ⅱ-1α和TNF-α的检测及意义[J].中华男科学,2004,10：449-450,454.
[50]Chemyshov VP.Lymphocyte response to phytomitogens in comparison to autoimmune Reactions and the state of spermatogenesis in urogenic experimental prostatitis in dogs[J]. Fiziolh, 1979,25(3):286.
[51]Casas Ingaramo A,Depiante-Depaoli M,Pacheco-Rupil B.Activation of cytotoxic cells by syngeneic prostate antigens in experimental autoimmune vesiculo-prostatitis[J]. Autoimmuntity, 1991,9(2):151-157.
[52]Maccioni M, Rivero VE, Riera CM. Prostatein(or rat prostatic steroid binding protein)is a major autoantigen in experimental autoimmune prostatitis[J]. Clin Exp Immunol,1998,112(2): 159-165.
[53]Maccioni M, Riera CM, Rivero VE.Identification of rat prostatic steroid binding protein (PSBP) as an immunosuppressive factor[J]. J Reprod Immunol,2001,50(2):133-149.
[54]周晓辉,韩蕾,周智恒,等.免疫性慢性非细菌性前列腺炎大鼠模型的形态学与分子生物学特性[J].中华男科学杂志,2005,11(4)：290-295.
[55]Zhou XH. Li LD, Wu LM, et al. Increased inflammatory factors activity in model rats with experimental autoimmune prostatitis[J]. Arch Androl,2005,11 (4):290-295.
[56]陈磊,夏卫平,周智恒.自身免疫性前列腺炎对大鼠前列腺形态学与炎性基因表达的影响[J].中华男科学杂志,2007,13(5)：444-448.
[57]Keith IM, Jin J, Neal D Jr, et al. Cell relationship in a Wistar rat model of spontaneous prostafitis[J]. J Uml,2001:166:323.
[58]KamiioT, Sato S, Kitamura T. Efect of cernitin polen-extract on experimental nonbacterial pmstatitis in rats[J]. Prostate,2001; 49:122-131.
[59]Harris MT, Feldberg RS, Lau KM, et al. Rat model of experimentaly induced abacterial prostatitis[J]. Prostate,2000,45(3):201-206.
[60]Wilson MJ, Woodson M, Wiehr C, et al. Matrix metallopmteinases in the pathogenesis of estradiol-induced nonbacterial prostatitis in the lateral prostate lobe of the Wistar rat[J]. Exp Mol Pathol,2004; 77:7-17.
[61]魏武然,张唯力,戴君勇.大鼠慢性非细菌性前列腺炎模型的建立[J].中国男科学杂志,2006：20：22-24.
[62]Takechi S, Yokoyama M, Tanji N, et. Nonbacterial prostafitis caused by part urethral obstruction in the rat[J]. urol Res,199927:346-350.
[63]戴岳,张聪。林巳笼,等.黄苓总苷对大鼠急慢性前列腺炎影响的实验研究[J].中医药学刊,2003,21：386.
[64]孙明杰,贾玉森,李军,等.前列腺炎栓药理学实验研究[J].中国中药杂志,2000；25：233-238.
[65]卢建新,张亚强，高筱松,等.丹蒲颗粒对实验性慢性非细菌性前列腺炎病理模型的影响[J].中医杂志,2003,44(9)：700-701.
[66]张远,穆松林,马述仕,等.消痔灵注射液的实验研究[J].中国中医杂志，1980,21(7)： 69-71.
[67]史兆岐.消痔灵注射液治疗三期内痔的体会[J].中医杂志,1980,21(7)：24-25.
[68]王天祥,徐岩.消痔灵注射液治疗海绵状血管瘤临床研究[J].临床皮肤科杂志,1987,16(1)：14-15.
[69]秦中平,孔庆旭.消痔灵注射液治疗血管瘤512例报告[J].中级医刊,1993,28(3)：28-29.
[70]邓春华,辛钟成,李宏军.男科病诊治学[M].广州：羊城晚报出版社,2004,1：393-401.
[71]李白华,王俊平.岩白菜素的研究概况[J].广州：羊城晚报出版社,2004,1：393-401.
[72]付静波,刘洪珍,赵彩霞.人体不同运动状态下血清乳酸含量和LDH、ACP、ALP活性的变化[J].现代康复,2000,4(10)：1514-1515.
[73]李江川,吴亚平,叶汉风.男性生育不育及节育者精浆中果糖和酸性磷酸酶的研究,云南医药[J].1990,11(5)：266.
[74]Shulman S.The detection of prostatic acid phosphatase by Antibody reaction sincell diffusion [J]. J Immunol,1964,93:474.
[75]李延平.慢性前列腺炎相关实验指标的变化及其意义[J].河南中医学院学报,2007,3(2)：86-89.
[76]马永江,安崇辰.中西医结合男科学[M].北京：中国中医药出版社,2001：662.
[77]Shahed AR, Shoskes DA. Oxidative stress in prostatic fluid of patients with chronic pelvic pain syndrome:correlation with gram positive bacterial growth and treatment response[J]. J Androl,2000,21:669-675.
[78]Vicari E, La Vignera S, Calogero AE. Antioxidant treatment with carnitines is effective in infertile patients with prostatovesiculoepididymitis and elevated seminal leukocyte concentrations after teratment with nonsteroidal anti-Inflammatory compounds[J]. Fertil Steril,2002,78(6): 1203-1208.
[79]Zhou JF. Xiao WQ, Zheng YC. et al. Increased oxidative stress and oxidative damage associated with chronic bacterial prostatitis[J]. Asian J Androl,2006,8(3):317-323.
[80]饶湘,林冠宇,宝丽,等.蜂花前清茶对前列腺炎大鼠治疗作用的研究[J].中药新药与临床药理,2008,19(5)：343-345.
[81]Hand G, Feneley MR.Smith D, et al. Androgens and the testis. Verh K Acad Geneeskd Belg, 1992,54:299.
[82]Reigman PHJ, Vliestra D, Lee S, et al. The promoter of the prostate specific antigen contains a functional androgen responsive element.Mol Endocrinol,1991,5:1921.
[83]Kinkead TM, Borzi PA,Duffy PG, et al.Long-term follow up of bladder mucosa graft for male urethral reconstruction.J Urol 1994,151(4):1056-1059
[84]Pontari MA, Ruggieri MR. J Urol 2004,172(3):839-845.
[85]Hinman F Jr. Atlas of urologic surgery.Philadelphia:WB Saunders,1989:22-23.
[86]Stein R, Thuroff JW. Hypospadias and bladder exstrophy.Curr Opin Urol 2002,12(3): 195-200.
[87]Fu Q, Deng CL. Ten-year experience with composite bladder mucosa-skin graft in hypospadi-as.J Urol 2006,67(6):1274-1277.
[2]居龙涛.虎耳草制剂治疗前列腺增生症[J].中国中医基础医学杂志,2007,13(1)：79-79.
[3]张立石,丁家欣,张秋海,等.虎耳草提取物对大鼠成纤维细胞的抑制作用[J].中国中医基础医学杂志,2005,11(12)：920-922.
[4]Morita N, et al. Chem Pharm Bull.1974,22(7):1487.
[5]罗厚蔚,吴葆金,陈节庵等.虎耳草有效成分研究[J].中国药科大学学报,1988,199(1)：1.
[6]周光兴.比较组织学彩色图谱[M].复旦大学出版社,2002：126.
[7]眭元庚.前列腺的组织结构、功能与疾病的关系[J].实用老年医学,2005,19(4)：172-173.
[8]厉将斌.慢性前列腺炎的中医认识和治疗思路[J].云南中医学院学报,2003,26(2)：29-31.
[9]陈武山.现代名中医男科学[M].北京：科学技术文献出版社,2002,1：124-125.
[10]王琦.临床医学丛书[M].北京：人民卫生出版社,2003,1：1213-1218.
[11]蒋毅,王久源,张蜀武,等.非淋煎口服液治疗衣原体、支原体感染性前列腺炎的临床应用研究[J].中华男科学,2003,9(4)：309-315.
[12]谭燕泉.清热解毒杀虫为法拟方内服外洗治疗滴虫性前列腺炎38例[J].安徽中医临志,2002,14(6)：465.
[13]邓春华,辛钟成,李宏军.男科病诊治学[M].广州：羊城晚报出版社,2004,1：393-401.
[14]郭应禄,李宏军,箭列腺炎[M].北京：人民军医出版社,2002,1：89-98.
[15]Collins MM. How common is prostatitis, A national survey of physician Visits[J]. J Urol. 1998,159(4):1224.
[16]Drach GW, Fair WR, Meares EM Jr, et al. Classification of benign disease associated with prostatic pain,prostatitis or prostatodynia[J]. J Urol.1978,120:266-270.
[17]Neisser A.Die Mikrokokken der ginorrhoe[J]. Dtsch Med Wochenser,1882,8:279-282.
[18]Meares EM,Stamey TA.Bacteriologic localization patterns in bacterial prostatitis and urethritis[J]. Invest Urol,1968,5(5):492-518.
[19]Blacklock NJ. The anatomy of the prostate:relation-ship with prostatic infection[J]. infection,1991,19:111-114.
[20]Zabokowski T,Peterek J,Srawarz B. The results of treatment of chronic prostatitis on the background of anaerobic bacterial and fugal infections[J]. WiadLek,1999,52:456-461.
[21]Nickel JC. Prostatitis:lessons from the 20th century[J]. Br Jurol,2000,85:179-185.
[22]Ye ZQ,Cai D,Lan RZ.et al. Biofeedbacktherapy for bacterial and nonbacterial prostatitis[J]. Urol,2000,85:179-185.
[23]Jackson E,Fowler JR.Antimicrobial therapy for bacterial and nonbacterial prostatitis[J]. Urol,2002,60(Suppl 6A):24-26.
[24]Nickel JC, Pontari M, Moon T, et al. A randomized placebo controlled multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic non-bacterial prostatitis[J]. Urol,2003,169(4):1401-1405.
[25]Shoskes DA. Phytotherapy in chronic prostatitis[J]. Uro,2002,60(6 Suppl):35-37.
[26]Nadler RB. Bladder training biofeedback and pelvic floor myalgia[J]. Urol,200260(6 Suppl):42-43.
[27]Zeitlin SI.Heat therapy in the treatment of prostatitis[J].Urol,2002,60 (6Suppl):38-40.
[28]Ye ZQ,Cai D,Lan RZ,et al. Biofeedback therapy for chronic pelvic pain Syndrome[J].Asian J Androl,2003,5(2):155-158.
[29]Mcnaughton Collins M,Wilt T.Allopurinol for chronic prostatitis[J].Cochrane Database Syst Rev,2000,2:1039-1041.
[30]Sboskes DA,Zeitlin SI,Shahed A,et al. Quercetin in men withcategoryⅢchronic prostatitis,a prelimi nary prospective,double-blind,place-controled trial[J].Urol,1999,54:960-963.
[31]于寿昌.慢性细菌性前列腺炎的感染菌调查[J].男性学杂志,1997,11：112.
[32]Zhang YY, Wang F, Zhang JD, et al.In vitro antibacterial activity of Levofloxacin[J]. Drugs, 1995,49 Suppl 2:274-275.
[33]那彦群,韩铁山,周利群,等.泰利必妥治疗慢性前列腺炎[J].中华泌尿外科杂志,1993,14(2)：144.
[34]吕建林.中西医结合治疗慢性细菌性前列腺炎[J].辽宁中医志,2003,9：755-756.
[35]吴在德.外科学(第5版)[M].北京：人民卫生出版社,2001.
[36]喻明清.中药灌肠结合头孢噻肟钠治疗慢性前列腺炎35例[J].广西中医学院学报,2003,6(2)：21-22.
[37]王庆相.慢性前列腺炎中西医结合治疗探讨[J].中国中西医结合外科杂志,2003,9(3)：200-201.
[38]潘锦堂.中国虎耳草属的研究[J].植物分类学报,1991,29(1)：1-24.
[39]刘文江,段育宏.中药百两金的药理作用[J].中草药,1986,17(9)：21.
[40]Lim H K. Ethnopharmacol,2000,72(3):469-474.
[41]湖南卫生局.矮地茶治疗老年性气管炎临床和试验研究资料[M].1972：46.
[42]吴春,孔琪,李健,等.槲皮素微胶囊的稳定性及缓释性能研究[J].化学与黏合,2006,28(1)：11-13.
[43]朱蕾,何丽娅.槲皮素抗癌作用的分子机制[J].武汉科技大学学报(自然科学),2004,27(2)：194-197.
[44]刘世旺,徐艳霞.虎耳草乙醇提取物抑菌作用的研究[J].资源开发与市场,2007,23(6)：481-482,489.
[45]刘世旺,徐艳霞,石宏武.虎耳草乙醇提取物对细菌生长曲线的影响[J].安徽农业科学,2007,35(4)：943-944,946.
[46]宋传旺.槲皮素对LPS延迟中性粒细胞自发性凋亡效应的抑制作用[J].中国免疫学杂志,2005,21：14-16.
[47]谢明辉.国外医药[J].植物药分册2002,17(6)：275.
[48]李宏军,商学军,黄宁烽.IL-10、IL-8在慢性前列腺炎中的改变及意义[J].中华男科学,2004，10：486-490.
[49]杨进益,叶林,姜洪波,等.慢性前列腺炎患者前列腺液Ⅱ-1α和TNF-α的检测及意义[J].中华男科学,2004,10：449-450,454.
[50]Chemyshov VP.Lymphocyte response to phytomitogens in comparison to autoimmune Reactions and the state of spermatogenesis in urogenic experimental prostatitis in dogs[J]. Fiziolh, 1979,25(3):286.
[51]Casas Ingaramo A,Depiante-Depaoli M,Pacheco-Rupil B.Activation of cytotoxic cells by syngeneic prostate antigens in experimental autoimmune vesiculo-prostatitis[J]. Autoimmuntity, 1991,9(2):151-157.
[52]Maccioni M, Rivero VE, Riera CM. Prostatein(or rat prostatic steroid binding protein)is a major autoantigen in experimental autoimmune prostatitis[J]. Clin Exp Immunol,1998,112(2): 159-165.
[53]Maccioni M, Riera CM, Rivero VE.Identification of rat prostatic steroid binding protein (PSBP) as an immunosuppressive factor[J]. J Reprod Immunol,2001,50(2):133-149.
[54]周晓辉,韩蕾,周智恒,等.免疫性慢性非细菌性前列腺炎大鼠模型的形态学与分子生物学特性[J].中华男科学杂志,2005,11(4)：290-295.
[55]Zhou XH. Li LD, Wu LM, et al. Increased inflammatory factors activity in model rats with experimental autoimmune prostatitis[J]. Arch Androl,2005,11 (4):290-295.
[56]陈磊,夏卫平,周智恒.自身免疫性前列腺炎对大鼠前列腺形态学与炎性基因表达的影响[J].中华男科学杂志,2007,13(5)：444-448.
[57]Keith IM, Jin J, Neal D Jr, et al. Cell relationship in a Wistar rat model of spontaneous prostafitis[J]. J Uml,2001:166:323.
[58]KamiioT, Sato S, Kitamura T. Efect of cernitin polen-extract on experimental nonbacterial pmstatitis in rats[J]. Prostate,2001; 49:122-131.
[59]Harris MT, Feldberg RS, Lau KM, et al. Rat model of experimentaly induced abacterial prostatitis[J]. Prostate,2000,45(3):201-206.
[60]Wilson MJ, Woodson M, Wiehr C, et al. Matrix metallopmteinases in the pathogenesis of estradiol-induced nonbacterial prostatitis in the lateral prostate lobe of the Wistar rat[J]. Exp Mol Pathol,2004; 77:7-17.
[61]魏武然,张唯力,戴君勇.大鼠慢性非细菌性前列腺炎模型的建立[J].中国男科学杂志,2006：20：22-24.
[62]Takechi S, Yokoyama M, Tanji N, et. Nonbacterial prostafitis caused by part urethral obstruction in the rat[J]. urol Res,199927:346-350.
[63]戴岳,张聪。林巳笼,等.黄苓总苷对大鼠急慢性前列腺炎影响的实验研究[J].中医药学刊,2003,21：386.
[64]孙明杰,贾玉森,李军,等.前列腺炎栓药理学实验研究[J].中国中药杂志,2000；25：233-238.
[65]卢建新,张亚强，高筱松,等.丹蒲颗粒对实验性慢性非细菌性前列腺炎病理模型的影响[J].中医杂志,2003,44(9)：700-701.
[66]张远,穆松林,马述仕,等.消痔灵注射液的实验研究[J].中国中医杂志，1980,21(7)： 69-71.
[67]史兆岐.消痔灵注射液治疗三期内痔的体会[J].中医杂志,1980,21(7)：24-25.
[68]王天祥,徐岩.消痔灵注射液治疗海绵状血管瘤临床研究[J].临床皮肤科杂志,1987,16(1)：14-15.
[69]秦中平,孔庆旭.消痔灵注射液治疗血管瘤512例报告[J].中级医刊,1993,28(3)：28-29.
[70]邓春华,辛钟成,李宏军.男科病诊治学[M].广州：羊城晚报出版社,2004,1：393-401.
[71]李白华,王俊平.岩白菜素的研究概况[J].广州：羊城晚报出版社,2004,1：393-401.
[72]付静波,刘洪珍,赵彩霞.人体不同运动状态下血清乳酸含量和LDH、ACP、ALP活性的变化[J].现代康复,2000,4(10)：1514-1515.
[73]李江川,吴亚平,叶汉风.男性生育不育及节育者精浆中果糖和酸性磷酸酶的研究,云南医药[J].1990,11(5)：266.
[74]Shulman S.The detection of prostatic acid phosphatase by Antibody reaction sincell diffusion [J]. J Immunol,1964,93:474.
[75]李延平.慢性前列腺炎相关实验指标的变化及其意义[J].河南中医学院学报,2007,3(2)：86-89.
[76]马永江,安崇辰.中西医结合男科学[M].北京：中国中医药出版社,2001：662.
[77]Shahed AR, Shoskes DA. Oxidative stress in prostatic fluid of patients with chronic pelvic pain syndrome:correlation with gram positive bacterial growth and treatment response[J]. J Androl,2000,21:669-675.
[78]Vicari E, La Vignera S, Calogero AE. Antioxidant treatment with carnitines is effective in infertile patients with prostatovesiculoepididymitis and elevated seminal leukocyte concentrations after teratment with nonsteroidal anti-Inflammatory compounds[J]. Fertil Steril,2002,78(6): 1203-1208.
[79]Zhou JF. Xiao WQ, Zheng YC. et al. Increased oxidative stress and oxidative damage associated with chronic bacterial prostatitis[J]. Asian J Androl,2006,8(3):317-323.
[80]饶湘,林冠宇,宝丽,等.蜂花前清茶对前列腺炎大鼠治疗作用的研究[J].中药新药与临床药理,2008,19(5)：343-345.
[81]Hand G, Feneley MR.Smith D, et al. Androgens and the testis. Verh K Acad Geneeskd Belg, 1992,54:299.
[82]Reigman PHJ, Vliestra D, Lee S, et al. The promoter of the prostate specific antigen contains a functional androgen responsive element.Mol Endocrinol,1991,5:1921.
[83]Kinkead TM, Borzi PA,Duffy PG, et al.Long-term follow up of bladder mucosa graft for male urethral reconstruction.J Urol 1994,151(4):1056-1059
[84]Pontari MA, Ruggieri MR. J Urol 2004,172(3):839-845.
[85]Hinman F Jr. Atlas of urologic surgery.Philadelphia:WB Saunders,1989:22-23.
[86]Stein R, Thuroff JW. Hypospadias and bladder exstrophy.Curr Opin Urol 2002,12(3): 195-200.
[87]Fu Q, Deng CL. Ten-year experience with composite bladder mucosa-skin graft in hypospadi-as.J Urol 2006,67(6):1274-1277.